Seeking Alpha

Raptor Pharmaceutical Corp. (RPTP)

  • Wed, Jan. 14, 9:42 AM
    • In an all-stock transaction, privately-held Tobira Therapeutics will merge with a wholly-owned subsidiary of Regado Biosciences (RGDO +59.3%). The combined organization, renamed as Tobira Therapeutics, will focus on the development of novel treatments for liver and inflammatory diseases. Tobira CEO Laurent Fischer, M.D., will lead the firm.
    • Tobira's lead product is cenicriviroc (CVC), a Fast Track-designated anti-fibrotic agent currently in Phase 2 development for non-alcoholic steatohepatitis (NASH).
    • A Tobira investor syndicate has committed to invest up to $22M to fund CVC's development through Phase 2. Tobira's quick asset balance will be ~$60M after the investment.
    • Under the terms of the merger, Regado shareholders will own ~32% of the combined entity while Tobira shareholders will own ~68%. The specific allocation will depend on Regado's net cash balance at the time of the transaction.
    | Wed, Jan. 14, 9:42 AM | 5 Comments
Company Description
Raptor Pharmaceutical Corp is a biopharmaceutical company. It is engaged in developing and commercializing transformative treatments for people affected by rare and debilitating diseases.